Ads
related to: simvastatin and heart attacks- Co-Pay Program
Resources
to Support Your Patients
- Dosing & Administration
Efficacy, Safety, and Dosing
Information for HCPs
- Request Samples
Get patients started
with a 14-day sample
- Trial Results
See Clinical Data
and Trial
- Co-Pay Program
Search results
Results From The WOW.Com Content Network
The Scandinavian Simvastatin Survival Study (also known as the 4S study), was a multicentre, randomized, double-blind, placebo-controlled clinical trial, which provided the initial data that supported the use of the cholesterol-lowering drug, simvastatin, in people with a moderately raised cholesterol and coronary heart disease (CHD); that is people who had previously had a heart attack or angina.
Simvastatin also reduced the numbers of other events like heart attacks, strokes, and revascularizations and MI significantly. [ 11 ] The Heart Protection Study evaluated the effects of simvastatin in people with risk factors including existing cardiovascular disease, diabetes, or stroke, but having relatively low LDL cholesterol.
It studied the use of the cholesterol lowering drug, simvastatin 40 mg and vitamin supplementation (vitamin E, vitamin C and beta carotene) in people who were at risk of cardiovascular disease. It was led by Jane Armitage, an epidemiologist at the Clinical Trial Service Unit. [1] [2]
Statins and heart disease in brief. Healthline spoke with Cheng-Han Chen, MD, a board-certified interventional cardiologist and medical director of the Structural Heart Program at MemorialCare ...
The cardiovascular disease lie is that statins are a good choice to prevent heart disease. What really causes heart disease? It’s complex. Statins — a class of prescription drugs that slow ...
It can increase the risk of serious cardiovascular events, such heart attack and stroke. Statins are a medication type that can help people at risk for atherosclerotic cardiovascular disease ...
Statin-induced hepatotoxicity can cause autoimmune hepatitis and an elevation in serum levels of hepatic enzymes such as alanine aminotransferase, impairing liver function. [20] Myotoxicity is commonly presented with statin-associated muscle symptoms (SAMS), which include myalgia and myositis. [21]
Using PREVENT to calculate the 10-year risk for developing heart disease, the researchers determined that some 40% fewer people would have met the criteria for a statin prescription.